Hydroxychloroquine: A physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 365, Issue 3, 2018, Pages 447-459

  Collins, Keagan P ^a   Jackson, Kristen M ^a   Gustafson, Daniel L ^a,b,c  

^a Engineering Research Center and Hydraulics Laboratory   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

H0915; HYDROXYCHLOROQUINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; VALIDATION PROCESS; ABSORPTION; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; TISSUE DISTRIBUTION;

ABSORPTION, PHYSICOCHEMICAL; ANIMALS; AUTOPHAGY; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MICE; MODELS, BIOLOGICAL; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 85046671704     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.245639     Document Type: Article

References (57)

1. Al-Bari MA (2015) Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70:1608–1621.
2. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, and White E (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:654–666.
3. Ballesta A, Zhou Q, Zhang X, Lv H, and Gallo JM (2014) Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT Pharmacometrics Syst Pharmacol 3:e112.
4. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, and Thamm DH (2014) Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 10:1415–1425.
5. Bischoff KB, Dedrick RL, Zaharko DS, and Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128–1133.
6. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–484.
7. Browning DJ (2014) Pharmacology of chloroquine and hydroxychloroquine, in Hydroxychloroquine and Chloroquine Retinopathy (Browning DJ ed) pp 35–63, Springer-Verlag, New York.
8. Carew JS, Kelly KR, and Nawrocki ST (2012) Autophagy as a target for cancer therapy: new developments. Cancer Manag Res 4:357–365.
9. Chiba M, Ishii Y, and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262–276.
10. Choi W, Baumann B, Liu JJ, Clermont AC, Feener EP, Duker JS, and Fujimoto JG (2012) Measurement of pulsatile total blood flow in the human and rat retina with ultrahigh speed spectral/Fourier domain OCT. Biomed Opt Express 3:1047–1061.
11. de Duve C (1983) Lysosomes revisited. Eur J Biochem 137:391–397.
12. Durairaj C, Chastain JE, and Kompella UB (2012) Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res 98:23–27.
13. Fan HW, Ma ZX, Chen J, Yang XY, Cheng JL, and Li YB (2015) Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC–MS/MS. Rheumatol Ther 2:183–195.
14. Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5 (Suppl 1):S11–S15.
15. Gustafson DL, Rastatter JC, Colombo T, and Long ME (2002) Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 91:1488–1501.
16. Ishizaki J, Yokogawa K, Ichimura F, and Ohkuma S (2000) Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. J Pharmacol Exp Ther 294:1088–1098.
17. Kawashima A, Sato A, Kawashima M, Nitta K, Yumura W, Sugino N, Nihei H, and Natori Y (1998) A simple procedure for the isolation of rat kidney lysosomes. Kidney Int 54:275–278.
18. Kim KA, Park JY, Lee JS, and Lim S (2003) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26:631–637.
19. Kornhuber J, Henkel AW, Groemer TW, Städtler S, Welzel O, Tripal P, Rotter A, Bleich S, and Trapp S (2010) Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system. J Cell Physiol 224:152–164.
20. Levy JM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, Morgan MJ, Mirsky DM, Handler MH, Foreman NK, et al. (2014) Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. Cancer Discov 4:773–780.
21. Levy JMM, Towers CG, and Thorburn A (2017) Targeting autophagy in cancer. Nat Rev Cancer 17:528–542.
22. Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, Kim TS, Choi JS, Jang IJ, and Park JW (2009) Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother 53:1468–1475.
23. Lu S, Sung T, Lin N, Abraham RT, and Jessen BA (2017a) Lysosomal adaptation: how cells respond to lysosomotropic compounds. PLoS One 12:e0173771.
24. Lu ZN, Tian B, and Guo XL (2017b) Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 80:925–937.
25. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, et al. (2014) Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10:1403–1414.
26. McChesney EW (1983) Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 75:11–18.
27. McChesney EW, Banks WF, Jr, and Fabian RJ (1967) Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. Toxicol Appl Pharmacol 10:501–513.
28. McChesney EW, Conway WD, Banks WF, Jr, Rogers JE, and Shekosky JM (1966) Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series. J Pharmacol Exp Ther 151:482–493.
29. McNally K, Cotton R, Hogg A, and Loizou G (2015) Reprint of PopGen: a virtual human population generator. Toxicology 332:77–93.
30. Meijer DK and van der Sluijs P (1989) Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery. Pharm Res 6:105–118.
31. Ohkuma S and Poole B (1978) Fluorescence probe measurement of the intra-lysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75:3327–3331.
32. Pandya HK, Robinson M, Mandal N, and Shah VA (2015) Hydroxychloroquine retinopathy: a review of imaging. Indian J Ophthalmol 63:570–574.
33. Pellegrini P, Strambi A, Zipoli C, Hägg-Olofsson M, Buoncervello M, Linder S, and De Milito A (2014) Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies. Autophagy 10:562–571.
34. Qi Z and Breyer MD (2009) Measurement of glomerular filtration rate in conscious mice. Methods Mol Biol 466:61–72.
35. Qu Y, Noe G, Breaud AR, Vidal M, Clarke WA, Zahr N, Dervieux T, Costedoat-Chalumeau N, and Blanchet B (2015) Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood. Future Sci OA 1:FSO26.
36. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, et al. (2014a) Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10:1391–1402.
37. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, et al. (2014b) Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10:1369–1379.
38. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, et al. (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10: 1359–1368.
39. Schroeder RL and Gerber JP (2014) Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies. Toxicol Rep 1:963–968.
40. Sewell RB, Dillon C, Grinpukel S, Yeomans ND, and Smallwood RA (1986) Peri-canalicular location of hepatocyte lysosomes and effects of fasting: a morphometric analysis. Hepatology 6:305–311.
41. Sheiner LB and Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–512.
42. Shi TT, Yu XX, Yan LJ, and Xiao HT (2017) Research progress of hydroxychloroquine and autophagy inhibitors on cancer. Cancer Chemother Pharmacol 79:287–294.
43. Tett S, Cutler D, and Day R (1990) Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol 4:467–489.
44. Tett SE, Cutler DJ, Day RO, and Brown KF (1988) A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 26:303–313.
45. Tett SE, Cutler DJ, Day RO, and Brown KF (1989) Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 27:771–779.
46. Thelen K and Dressman JB (2009) Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61:541–558.
47. Trapp S and Horobin RW (2005) A predictive model for the selective accumulation of chemicals in tumor cells. Eur Biophys J 34:959–966.
48. Trapp S, Rosania GR, Horobin RW, and Kornhuber J (2008) Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J 37:1317–1328.
49. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, et al. (2014) Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10:1380–1390.
50. Warhurst DC, Steele JC, Adagu IS, Craig JC, and Cullander C (2003) Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 52:188–193.
51. Wei Y, Nygard GA, Ellertson SL, and Khalil SK (1995) Stereoselective disposition of hydroxychloroquine and its metabolite in rats. Chirality 7:598–604.
52. Yang ZJ, Chee CE, Huang S, and Sinicrope FA (2011) The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10:1533–1541.
53. Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, and Oudit GY (2014) Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol 30:1706–1715.
54. Zhang L and Mager DE (2015) Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. J Pharmacokinet Phar-macodyn 42:541–552.
55. Zhi Z, Yin X, Dziennis S, Wietecha T, Hudkins KL, Alpers CE, and Wang RK (2012) Optical microangiography of retina and choroid and measurement of total retinal blood flow in mice. Biomed Opt Express 3:2976–2986.
56. Zhitomirsky B and Assaraf YG (2014) Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget 6:1143–1156.
57. Zhitomirsky B and Assaraf YG (2015) The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes. Cancer Cell Microenviron 2:e807.